Assessment of efficacy and safety of dose-dense doxorubicin and cyclophosphamide (ddAC) in combination with immunotherapy in early-stage triple-negative breast cancer
Breast Cancer Research and Treatment · 2024-08 · 207 (1) · 179-185
DOI: 10.1007/s10549-024-07354-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, online erschienen am 21.05.2024. Verfasst von Olivia White und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Virginia Health System, Charlottesville, VA, USA. olivia.white@virginia.edu. Hauptthemen laut MEDLINE: Cyclophosphamide, Doxorubicin, Triple Negative Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
This study aimed to assess safety and efficacy of a modified KEYNOTE 522 protocol, which incorporated pembrolizumab every 6 weeks, allowing for concomitant dose-dense (14 day) doxorubicin and cyclophosphamide (ddAC). By optimizing this dosing, the intention of this modified protocol was to improve pathologic complete response (pCR) rates in a population associated with a poorer prognosis.
Methods
This was a retrospective, single-center, cohort study. Patients were included if they had early stage, triple-negative breast cancer, and received at least one dose of AC. The entire cohort received neoadjuvant chemotherapy including weekly carboplatin and paclitaxel with pembrolizumab every 3 weeks for 12 weeks (4 cycles). The group then received either ddAC with pembrolizumab 400 mg every 6 weeks, or AC with pembrolizumab 200 mg every 3 weeks. The primary objective was pCR rate at time of surgery.
Results
This study assessed outcomes in 25 patients over 34 months. The pCR rate in the pembrolizumab, AC 3-week cohort was 64.3% versus 81.8% in the ddAC and 6-week pembrolizumab group. No pembrolizumab-associated grade 3–4 adverse events occurred in the either cohort. Despite seeing an increased incidence of grade 3–4 toxicities in the ddAC arm, this did not result in additional chemotherapy delays or dose reductions.
Conclusion
This study demonstrated tolerability and a potential for favorable outcomes with this patient population, making this modified KEYNOTE 522 protocol a reasonable treatment approach. Larger, prospective studies are warranted to assess the feasibility of this dosing and true optimization of patient outcomes given the small sample size of this study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, University of Virginia Health System, Charlottesville, VA, USA. olivia.white@virginia.edu.
- Duke Cancer Institute, Durham, NC, USA.
- Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.
Zitieren
APA
White, O., Dent, S., Westbrook, K., Lee, H. J., Yang, C., & Moore, H. N. (2024). Assessment of efficacy and safety of dose-dense doxorubicin and cyclophosphamide (ddAC) in combination with immunotherapy in early-stage triple-negative breast cancer. Breast Cancer Research and Treatment, 207(1), 179-185. https://doi.org/10.1007/s10549-024-07354-2
Vancouver
White O, Dent S, Westbrook K, Lee HJ, Yang C, Moore HN. Assessment of efficacy and safety of dose-dense doxorubicin and cyclophosphamide (ddAC) in combination with immunotherapy in early-stage triple-negative breast cancer. Breast Cancer Research and Treatment. 2024;207(1):179-185. doi:10.1007/s10549-024-07354-2
BibTeX
@article{White2024,
author = {White, Olivia and Dent, Susan and Westbrook, Kelly and Lee, Hui-Jie and Yang, Chengxin and Moore, Heather N},
title = {Assessment of efficacy and safety of dose-dense doxorubicin and cyclophosphamide (ddAC) in combination with immunotherapy in early-stage triple-negative breast cancer},
journal = {Breast Cancer Research and Treatment},
year = {2024},
volume = {207},
number = {1},
pages = {179--185},
doi = {10.1007/s10549-024-07354-2}
}
EUVIMED